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CD73, a cell-surface N-linked glycoprotein that produces extracellular adenosine, is a novel target for cancer im-
munotherapy. Although anti-CD73 antibodies have entered clinical development, CD73 has both protumor and an-
titumor functions, depending on the target cell and tumor type. The aim of this study was to characterize CD73 
regulation in human hepatocellular carcinoma (HCC). We examined CD73 expression, localization, and activity 
using molecular, biochemical, and cellular analyses on primary HCC surgical specimens, coupled with mechanistic 
studies in HCC cells. We analyzed CD73 glycan signatures and global alterations in transcripts encoding other N-
linked glycoproteins by using mass spectrometry glycomics and RNA sequencing (RNAseq), respectively. CD73 was 
expressed on tumor hepatocytes where it exhibited abnormal N-linked glycosylation, independent of HCC etiology, 
tumor stage, or fibrosis presence. Aberrant glycosylation of tumor-associated CD73 resulted in a 3-fold decrease 
in 5′-nucleotidase activity (P  <  0.0001). Biochemically, tumor-associated CD73 was deficient in hybrid and com-
plex glycans specifically on residues N311 and N333 located in the C-terminal catalytic domain. Blocking N311/
N333 glycosylation by site-directed mutagenesis produced CD73 with significantly decreased 5′-nucleotidase activity 
in vitro, similar to the primary tumors. Glycosylation-deficient CD73 partially colocalized with the Golgi struc-
tural protein GM130, which was strongly induced in HCC tumors. RNAseq analysis further revealed that N-linked 
glycoprotein-encoding genes represented the largest category of differentially expressed genes between HCC tumor 
and adjacent tissue. Conclusion: We provide the first detailed characterization of CD73 glycosylation in normal and 
tumor tissue, revealing a novel mechanism that leads to the functional suppression of CD73 in human HCC tumor 
cells. The present findings have translational implications for therapeutic candidate antibodies targeting cell-surface 
CD73 in solid tumors and small-molecule adenosine receptor agonists that are in clinical development for HCC. 
(Hepatology Communications 2019;3:1400-1414).
Ecto-5′-nucleotidase (CD73) is the major enzyme that dephosphorylates extracellular adenosine 5′-monophosphate (AMP) to produce adenos-
ine. CD73 activity is ubiquitous in mammalian systems 
and regulates purine salvage and purinergic signaling 
in tissue homeostasis, inflammation, fibrosis, and can-
cer.(1,2) CD73-generated adenosine can suppress antitu-
mor T-cell responses, thereby promoting the progression 
of breast, skin, ovarian, and prostate cancer in animal 
models.(3) Several anti-CD73 inhibitory antibodies 
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(MEDI9447, CPI-006, TJ004309, NZV930) are cur-
rently undergoing clinical testing for advanced solid 
tumors.(4,5) However, the role of CD73 in cancer is 
complex because CD73 activity is crucial for protecting 
endothelial and epithelial barrier functions,(6) particu-
larly during hypoxic conditions,(7,8) and CD73 protects 
the epithelial integrity in well-differentiated early stage 
endometrial carcinoma, which is associated with bet-
ter overall patient survival.(9) This clearly demonstrates 
that the role of CD73 in cancer is not uniform and 
warrants a critical mechanistic evaluation of CD73 
regulation and function at multiple levels and in differ-
ent cancer types.(6)
CD73 is a known regulator of hepatocyte 
injury(10,11) and fibrogenic responses in the liver,(12,13) 
but its functional regulation in liver cancer has not 
been investigated to date. Given the importance of 
CD73 as a novel target for cancer therapy and the 
significant disease burden of liver cancer,(14) the aim 
of the present study was to investigate the regulation 
and activity of CD73 protein in human hepatocellu-
lar carcinoma (HCC). CD73 is widely expressed in 
hepatobiliary malignancies, and aberrant intense cyto-
plasmic CD73 staining is a marker of invasive lesions 
in HCC.(15) The mechanisms behind the aberrant 
CD73 localization and whether it is enzymatically 
active are not known. Novel interventions for HCC 
are critically needed, and modulation of adenosine 
signaling represents one potential strategy. Specifically, 
the adenosine A3 receptor (A3AR) is highly expressed 
in HCC, and its activation by a selective agonist 
(2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-methy-
luronamide [CF102 or Namodenoson]) has antitumor 
effects in a rat model of HCC.(16) CF102 recently 
completed phase II clinical testing and showed a 
favorable clinical safety profile and a positive signal 
of efficacy in patients with advanced HCC and severe 
liver dysfunction, justifying further testing in phase III 
trials.(17,18) In light of the important role of adenosine 
signaling as a clinical target in HCC, it is critical to 
understand how the activity of the major extracellular 
AMPase CD73 is regulated in HCC tumors.
As a glycosylphosphatidylinositol-anchored protein 
(GPI-AP), CD73 undergoes complex processing by 
the secretory pathway.(19) Proteins destined for this 
pathway undergo initial maturation in the endoplas-
mic reticulum (ER) followed by vesicular transport 
through the Golgi apparatus before being targeted to 
their ultimate destinations through the trans-Golgi 
network. A key regulatory step in the proper execu-
tion of this process is the sequential covalent mod-
ification of proteins with oligosaccharides linked 
by asparagine residues, termed N-linked glycosyla-
tion.(20) Alterations in the N-linked glycoproteome 
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are hallmarks of many cancers, including HCC.(21) 
In this study, we reveal a novel glycosylation mech-
anism leading to the mislocalization and functional 
suppression of CD73 in HCC tumors. Our results 
illuminate specific regulatory mechanisms that may be 
exploited for targeted treatment to improve outcomes 
in patients with HCC.
Materials and Methods
antiBoDies anD Reagents
Mouse anti-Flag M2 clone (Sigma-Aldrich) 
and rabbit anti-CD73 clone HPA017357 (Atlas 
Antibodies) were used to detect tagged and untagged 
(endogenous) CD73, respectively. Mouse anti-CD73 
clone AD2 (BD Biosciences) was used for immuno-
precipitation of CD73. Mouse anti-CD73 clone IE9 
(Santa Cruz Biotechnology) was used to costain with 
tight junction markers ZO1 (rabbit; Cell Signaling) 
and claudin-1 (rabbit; Thermo Fisher Scientific). 
Other antibodies used were rat anti-keratin (K)19 
(Troma-III; Developmental Studies Hybridoma 
Bank); rabbit anti-tissue nonspecific alkaline phospha-
tase (TNAP; Abcam); and mouse monoclonal anti-
bodies for Golgi marker proteins GM130, Vti1, STx6, 
and GS27 (BD Biosciences). Complementary DNA 
encoding human ecto-5′-nucleotidase (NT5E)-1 and 
NT5E-2 in pCMV6-Entry and control empty vec-
tor were purchased from Origene. Endoglycosidase 
H (EndoH) and peptide:N-glycosidase F (PNGase 
F) glycosidases were used with liver lysates as recom-
mended by the manufacturer (New England Biolabs).
Human speCimens
Surgical specimens were collected under approved 
human subjects protocols at the University of 
Michigan (UM) and the University of North Carolina 
at Chapel Hill (UNC). HCC surgical specimens that 
were collected at UM have been described.(22) Normal 
human liver specimens were from surgical resections 
of unaffected liver tissue collected during removal of 
colorectal cancer metastasis to the liver. An additional 
27 liver–tumor pairs of HCC surgical specimens (23 
of which were CD73 positive) were collected at UNC 
under an approved human subject protocol (clinical 






Huh7 cells were obtained from the Japanese 
Collection of Research Bioresources and cultured in 
Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum and 100  U/mL peni-
cillin/streptomycin. PLC/PRF5 cells were from the 
American Type Culture Collection (ATCC; Manassas, 
VA) and cultured according to ATCC recommen-
dations. Site-directed mutagenesis was performed 
using the QuikChange kit (Agilent Technologies). 
For immunofluorescence analysis, human tissues or 
cells were fixed in methanol at −20°C for 10 minutes, 
washed 3  times in phosphate-buffered saline (PBS) 
and incubated in blocking solution (2.5% bovine 
serum albumin, 2% normal goat serum in PBS) for 
1 hour at room temperature. Primary antibodies were 
diluted in blocking buffer and incubated overnight 
at 4°C. Following three PBS washes, the cells/tissues 
were incubated with Alexa Fluor-conjugated second-
ary antibodies diluted in blocking solution for 1 hour 
at room temperature followed by 4′,6-diamidino- 
2-phenylindole (DAPI) incubation for 5  minutes 
and mounted in Fluoromount-G (SouthernBiotech, 
Birmingham, AL) overnight. Secondary antibodies 
alone served as negative controls. A Zeiss 880 confo-
cal laser scanning microscope using a 63× (1.4 numer-
ical aperture) oil immersion objective (Zeiss, Jena, 
Germany) was used for imaging.
BioCHemiCal assay oF CD73 
eXpRession anD aCtiVity
CD73 was extracted from cells or liver tissue in 
50 mM n-octylglucoside (Sigma) in PBS (OG lysis 
buffer) with freshly added complete protease inhibi-
tor cocktail (Roche) and shaking for 2  hours at 4°C, 
followed by centrifugation at 20,000g for 20  min-
utes. Immunoprecipitation of CD73 from OG lysates 
was performed using Dynabeads protein G (Thermo 
Fisher Scientific) following the manufacturer’s 
instructions. Measurement of 5′-nucleotidase activ-
ity was performed using a commercial kit (Diazyme) 
with OG liver lysates that were first normalized to 
1  mg/mL total protein concentration. This assay is 
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based on a four-reaction sequence beginning with the 
enzymatic hydrolysis of 5′-inosine monophosphate 
(5′-IMP) to form inosine, which is subsequently con-
verted to hypoxanthine by purine nucleoside phos-
phorylase. Xanthine oxidase converts hypoxanthine to 
uric acid and hydrogen peroxide (H2O2). H2O2 is then 
reacted with N-ethyl-N-(2-hydroxy-3-sulfopropyl)-
3-methylaniline and 4- aminoantipyrine in the pres-
ence of peroxidase to generate a quinone dye, which is 
monitored in a kinetic manner. The specificity of the 
5′-IMP-based assay for CD73 activity was originally 
described in multiple tissues(8) and specifically in the 
liver, using CD73−/− liver lysates.(11)
mass speCtRometRy 
analysis oF site-speCiFiC 
CD73 glyCosylation anD 
DeteRmination oF glyCan 
stRuCtuRes
CD73 was immunodepleted from liver and tumor 
OG lysates and subjected to mass spectrometry (MS) 
analysis to determine site-specific glycosylation and gly-
can structures. The band corresponding to CD73 pro-
tein was excised and destained with 30% methanol for 
4  hours. Following reduction (10  mM dithiothreitol) 
and alklylation (65 mM 2-chloroacetamide) of the cys-
teines, proteins were digested overnight with sequenc-
ing-grade modified trypsin (Promega). Resulting 
peptides were resolved on a nanocapillary reverse phase 
column (Acclaim PepMap C18, 2 μm, 15 cm; Thermo 
Scientific, San Jose CA) using a 1% acetic acid/acetoni-
trile gradient at 300 nL/minute and were directly intro-
duced into an Orbitrap Fusion tribrid MS (Thermo 
Scientific). MS1 scans were acquired at 60K resolu-
tion. Data-dependent high-energy C-trap dissociation 
MS/MS spectra were acquired with top-speed option 
(3 seconds) following each MS1 scan (relative capillary 
electrophoresis ~35%). Fragment (daughter) ion masses 
were measured in orbitrap (resolution of 15K). XX 
peptide identification and site-specific glycan struc-
tures were determined using the program GP Finder, 
as described.(23) To determine glycopeptide abundance, 
we used the summation of elution apex intensities of 
all MS1 isotope peaks. MS1 precursor features of gly-
copeptides were extracted by the feature detection algo-
rithm described in DIA-Umpire.(24) Feature detection 
was restricted to +3, +4, and +5 charge states and 3-5 
isotope peaks. For each liquid chromatography (LC)/
MS run, the detected features with close precursor 
mass-to-charge ratio (±20 ppm) and charge state iden-
tical to the identified glycopeptides were considered as 
the candidate features for quantification. For the iden-
tified glycopeptides, the feature closest to the identified 
retention time was extracted. If a glycopeptide was only 
identified in other LC/MS runs, the most intense can-
didate feature within a 2-minute retention time range 
of the identified retention times from other LC/MS 
runs was extracted.
Rna seQuenCing analysis oF 
DiFFeRentially eXpResseD 
genes in aDJaCent nontumoR 
liVeR tissue anD HCC tumoR 
tissue
Surgical tissues from two adjacent liver–tumor pairs 
were preserved in RNAlater. Tumor CD73 displayed shift 
in migration on sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) in both specimens. 
RNA was extracted using the RNeasy kit (Qiagen) and 
used for sequencing analysis (all RNA integrity number 
values were >9). For the published dataset (GSE 33294), 
sequence read archive data files were obtained from the 
National Center for Biotechnology Information (NCBI) 
Gene Expression Omnibus repository and converted 
into fastq files. The quality of the raw reads data was 
determined using FastQC. The software package Tuxedo 
Suite was used for alignment, differential expression 
analysis, and postanalysis diagnostics. FastQC was used 
for a second round of quality control (postalignment) 
to ensure that only high quality data would be input 
to expression quantitation and differential expression 
analysis. We used Cufflinks/CuffDiff (version 2.1.1) for 
expression quantitation and differential expression anal-
ysis, using University of California Santa Cruz (UCSC) 
hg19.fa as the reference genome sequence and UCSC 
hg19.gtf as the reference transcriptome annotation. We 
identified genes and transcripts as being differentially 
expressed based on three criteria: test status, “OK”; false 
discovery rate, <0.05; and fold change, ≥1.5. We anno-
tated genes and isoforms with NCBI Entrez GeneIDs 
and text descriptions. We further annotated differentially 
expressed genes with gene ontology terms using NCBI 
annotation. We used DAVID (version 6.7) for enrich-
ment analysis of the set of differentially expressed genes 
Hepatology CommuniCations, october 2019ALCEDO ET AL.
1404
to identify significantly enriched functional categories; 
these are presented in Supporting File S2.
Results
CD73 is eXpResseD in 
malignant HepatoCytes 
anD eXHiBits CytoplasmiC 
DistRiBution in HCC tumoRs
Using data from the PanCancer Atlas Consortium,(25) 
we determined that the CD73-encoding gene (NT5E) 
did not correlate with a specific tumor immune subtype 
in HCC (Fig. 1A). However, aside from its functions in 
the immune system, CD73 is also a well-known regulator 
of epithelial cells,(6) including hepatocytes.(11) Therefore, 
we investigated CD73 protein expression and localiza-
tion in nondiseased (normal) liver and HCC tumor and 
adjacent nontumor tissues. Immunofluorescence imag-
ing revealed abundant CD73 expression in normal liver 
and in HCC (Fig. 1B). CD73 in HCC adjacent liver 
tissue and tumor tissue appeared largely intracellular 
(Fig. 1B). Costaining with the tight junction marker 
ZO1 revealed CD73 presence in the cytoplasm as well 
as the lumen of bile canaliculi in adjacent liver tissue 
Fig. 1. CD73 is highly expressed in malignant hepatocytes in human HCC. (A) NT5E gene expression across tumors classified into 
the four major HCC immune subtypes: wound healing (C1), IFNγ-dominant (C2), inf lammatory (C3), and lymphocyte depleted 
(C4). Data were obtained from the PanCancer Atlas (one-way ANOVA; Tukey’s multiple comparisons test). (B) Immunofluorescence 
analysis of CD73 (green) and DAPI-stained DNA (blue) in normal human liver tissue (left), HCC adjacent liver tissue (middle), 
and tumor tissue (right). Scale bars, 50 μm. (C) Immunofluorescence analysis of CD73 (magenta), ZO1 (green), and DAPI-stained 
DNA (blue). Bottom panels represent boxed areas of the merged images, revealing cytoplasmic (asterisk) and punctate perinuclear 
(arrowhead) clustering of CD73 in HCC tumor and adjacent tissue. In adjacent liver tissue, CD73 was also localized in the lumen of 
the bile canaliculus (arrows). Scale bars, 20 μm. (D) Immunofluorescence analysis of DAPI-stained DNA (blue), CD73 (green), and 
K8 and K19 (red), which mark hepatocytes and cholangiocytes, respectively. Scale bars, 50 μm. Abbreviations: FPKM, fragments per 
kilobase of exon model per million reads mapped; IFN, interferon; ns, no statistical significance in expression between groups.
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and primarily cytoplasmic and perinuclear distribution 
in the tumor tissue (Fig. 1C). To determine which epi-
thelial cell types express CD73 in HCC tumors, we 
costained for the epithelial markers K8 and K19. CD73 
is abundant in K8-positive but not K19-positive cells 
(Fig. 1D), suggesting that it is expressed primarily on 
malignant hepatocytes and absent from tumor cholan-
giocytes. By immunoblot analysis, we detected CD73 
protein in all HCC cell lines we tested (Hep3B, Huh7, 
MHCC97, SNU-423, and SNU-449), while PLC/
PRF/5 hepatoma cells were CD73 negative (Fig. 2A). 
Immunofluorescence analysis confirmed the lack of 
CD73 in the PLC/PRF5 cells (Fig. 2B) and revealed 
cytoplasmic and membranous distribution of CD73 in 
the Huh7 cells (Fig. 2B,C). Specifically, costaining with 
the tight junction markers ZO1 and claudin-1 showed 
CD73 localization within the lumen of small bile can-
aliculi-like structures (Fig. 2C, arrows) that Huh7 cells 
are known to form in culture(26) as well as the presence 
of CD73 in perinuclear puncta (Fig. 2C, arrowheads), 
similar to its distribution in the primary HCC tissues.
tumoR-speCiFiC BioCHemiCal 
CHanges on CD73 
CoRRelate WitH DeCReaseD 
5′-nuCleotiDase aCtiVity
HCC typically develops in the context of cirrho-
sis, so we asked whether CD73 protein expression is 
different in the tumor versus the adjacent nontumor 
tissue. Immunoblot analysis (Fig. 3A) and quanti-
fication of band intensities from 23 CD73-positive 
HCC liver–tumor pairs (Fig. 3B; Supporting File S1) 
revealed heterogeneous expression of CD73. Of the 
23 tumors, CD73 was increased in 11, unchanged in 
six, and decreased in six tumors, relative to adjacent 
liver. However, we also noted that in 13/23 (57%) 
of the CD73-positive liver–tumor pairs, CD73 from 
the tumor tissue migrated faster on SDS-PAGE gels 
compared to CD73 from adjacent nontumor liver, 
as shown by the representative immunoblot in Fig. 
3C. Tumor-associated biochemical changes in CD73 
were independent of HCC etiology, tumor stage, and 
Fig. 2. CD73 is endogenously expressed in human HCC cell lines and exhibits membrane and cytoplasmic expression. (A) CD73 
immunoblot and Coomassie stain (loading control) in HCC cell lines. (B) Immunofluorescence staining of CD73 (green) and DNA 
(blue) in Huh7 (CD73-positive) and PLC/PRF5 (CD73-negative) cell lines. Scale bars, 20 μm. (C) Immunofluorescence analysis of 
CD73 (magenta), ZO1 or claudin-1 (green; as labeled in panels), and DAPI-stained DNA (blue) in Huh7 cells. Bottom panels represent 
boxed areas of the merged images, revealing membrane (arrows) and punctate cytoplasmic (arrowheads) localization. Scale bars, 40 μm.
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Fig. 3. HCC tumor-specific CD73 biochemical alterations correlate with decreased 5′-nucleotidase activity. (A) Representative 
immunoblot (top) of CD73 in adjacent liver and tumor OG lysates from surgical HCC specimens collected at UNC. Coomassie-stained 
gel serves as a loading control. The numbers represent individual patients. (B) Densitometric quantification of CD73 protein from 
immunoblot analysis of 23 pairs of adjacent liver and tumor tissues from patients with HCC. (C) Representative CD73 immunoblots of 
HCC adjacent liver and tumor tissue OG lysates from 2 patients, demonstrating differences in tumor CD73 migration on SDS-PAGE. 
(D-F) Distribution of (D) HCC etiology, (E) tumor stage, and (F) fibrosis status across tumor samples without CD73 shift (left bars; 
n = 10) and with CD73 shift (right bars; n = 12-13). Clinical and biochemical data on all samples are provided in Supporting File S1. 
(G) Measurement of 5′-nucleotidase activity in adjacent liver and tumor tissue OG lysates from HCC cases in which tumor CD73 
did not exhibit a shift in migration (left panel; cases similar to #509 in C) and in HCC cases where there was a significant shift (right 
panel; cases similar to #275 in C). Box and whiskers plot. ****P < 0.0001; paired t test. Abbreviations: L, adjacent liver tissue; NAFLD, 
nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; T, tumor tissue; WB, western blot.
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presence of fibrosis (Fig. 3D-F). However, altered bio-
chemical processing of CD73 in the HCC tumors 
was associated with significantly decreased enzymatic 
activity (Fig. 3G). Although there was a negative cor-
relation trend between CD73 shift with disease-free 
status (P = 0.20) and patient survival (P = 0.28), it was 
not statistically significant (Supporting Fig. S1A-C). 
Similarly, total tumor CD73 expression did not cor-
relate with clinical outcomes based on the samples 
tested here (Supporting Fig. S1D-F).
CD73 unDeRgoes 
DiFFeRential glyCosylation 
in HCC tumoRs RelatiVe to 
aDJaCent nontumoR tissue
CD73 has four consensus N-glycosylation motifs: 
53NAS, 311NSS, 333NYS, and 403NGT (Fig. 4A). 
Changes in glycosylation at one or more of these sites 
may alter CD73 activity because three (N311/N333/
N403) are located in the C-terminal catalytic domain 
of the molecule.(19) Therefore, we tested the hypothe-
sis that tumor CD73 undergoes altered glycosylation. 
To that end, we deglycosylated CD73 in vitro using 
EndoH (typically removes immature high mannose 
glycans introduced in the ER) and PNGase F (removes 
more mature complex glycans introduced post-ER 
exit). The differential migration on the gel was not 
present after PNGase F treatment but was still present 
in the EndoH-resistant fraction (Fig. 4B). This sug-
gested that glycosylation differences on tumor CD73 
are introduced after exit from the ER. MS glycomics 
analysis revealed that the majority of CD73 glycans 
are conjugated to N311 and N333, followed by N403 
and N53 (Fig. 4C). While N333 was conjugated pri-
marily to complex glycans, N311 displayed a mix of 
high mannose, hybrid, and complex glycans (Fig. 4D). 
Globally, the major glycosylation differences on CD73 
from HCC tumors were in specific glycan structures, 
with a significant increase in high mannose glycans and 
a decrease in hybrid glycans (Fig. 5A). The greatest gly-
cosylation changes were observed at site N311 (Fig. 5B), 
where under normal conditions high mannose glycans 
accounted for <20% of all glycans; in tumor CD73, 
this residue was highly mannosylated (>60% of total 
glycans). In addition, incorporation of complex glycans 
was significantly reduced at both the N311 and N333 
sites (Fig. 5B,C).
site-speCiFiC glyCosylation 
Regulates CD73 enZymatiC 
aCtiVity anD suBCellulaR 
DistRiBution
To assess the functional significance of site-specific 
CD73 N-glycosylation, we generated nonglycosylat-
able mutants (N311Q and N333Q) and compared their 
enzymatic activity to wild-type (WT) CD73 (Fig. 5D). 
The glycosylation-deficient N311Q and N333Q 
mutants had 30% and 50% lower enzyme activity, 
respectively, compared to WT CD73. Furthermore, 
the subcellular distribution of both mutants appeared 
predominantly perinuclear compared to WT CD73 
(Fig. 5E). To assess whether the intracellular CD73 
puncta colocalize with the Golgi organelle, where most 
of the hybrid and complex glycans are conjugated to 
proteins, we costained with the Golgi marker GM130. 
The glycosylation-deficient and catalytically-impaired 
N333Q mutant partially colocalized with GM130 
(Fig. 5F), suggesting that it is partly retained in the 
Golgi compartment. Combined, these data demon-
strate that N-glycosylation of CD73 at N311 and 
N333, the two sites that are aberrantly glycosylated 
on CD73 in primary HCC tumors, is important for 
CD73 function.
up-Regulation oF golgi 
pRotein gm130 anD 
gloBal DiFFeRenCes in 
tHe eXpRession oF genes 
enCoDing N-linKeD 
glyCopRoteins in HCC tumoRs
We analyzed major proteins that regulate the tran-
sit of GPI-APs through the Golgi organelle, includ-
ing GM130, which is important for glycosylation 
and maintenance of Golgi structure; the v-SNARE 
(Vti1) and t-SNARE (syntaxin-6) proteins involved 
in vesicle transport through the Golgi, and a SNAP 
receptor that regulates protein transport in the Golgi 
(GS27). GM130 exhibited the most profound differ-
ences between tumor and adjacent nontumor tissue and 
was up-regulated more than 8-fold in HCC tumors 
(Fig. 6A,B). While in adjacent nontumor human liver 
tissue, GM130 staining appeared as perinuclear puncta; 
in HCC tumors, the puncta appeared enlarged and 
merged, forming larger structures (Fig. 6C).
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Fig. 4. Site-specific glycan distribution on CD73 in normal human liver. (A) Model of CD73 dimer structure (magenta) showing 
the four asparagine residues (yellow) that are targets of glycosylation. Structure of CD73 dimer was generated using Pymol (PDB: 
4H1S). (B) Effect of in vitro CD73 deglycosylation using PNGase F or EndoH. (C) Relative abundance of glycans across the four 
CD73 N-linked glycosylation sites, demonstrating that N311 and N333 account for >70% of all glycans. Bars represent mean ± SD. 
*P < 0.05; **P < 0.01; ***P < 0.001; one-way ANOVA Tukey’s multiple comparisons test. (D) Types of glycans present on the four CD73 
glycosylation sites. GlcNAc ( ), mannose ( ), fucose ( ), galactose ( ), Neu5Ac ( ).
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Fig. 5. Site-specific increase in high mannose glycans promotes CD73 intracellular retention and decreased enzymatic activity. 
(A) Percent of high mannose (top), hybrid (middle), and complex (bottom) glycans on CD73 extracted from normal liver tissue (non-
HCC; n = 4), HCC adjacent liver tissue (n = 5), and HCC tumor tissue (n = 5). Bars represent mean ± SD. *P < 0.05; ***P < 0.001; 
one-way ANOVA. (B,C) Changes in glycan composition on the two major CD73 glycosylation sites, N311 and N333. **P < 0.01; 
***P < 0.001; ****P < 0.0001. Bars represent mean ± SD. (D) Representative CD73 immunoblot (top) of PLC/PRF/5 cells transfected 
with empty vector, WT CD73, and glycosylation mutants N311Q and N333Q , demonstrating equal overexpression of CD73 protein. 
Measurement of 5′-nucleotidase activity (bottom) in lysates of control vector-transfected (−) or CD73-transfected PLC/PRF/5 cells 
(n = 3). Data are representative of at least three independent experiments. Bars represent mean ± SD. **P < 0.01; ***P < 0.001; one-way 
ANOVA. (E) Subcellular distribution of WT and glycosylation point mutant CD73 transfected in PLC/PRF/5 cells. Green, CD73; 
blue, DNA. Scale bars, 10 μm. (F) Colocalization between CD73-N333Q (green) and the Golgi marker protein GM130 (red). Scale 
bar, 20 μm. Abbreviation: HM, high mannose.
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Fig. 6. Increased expression of the Golgi protein GM130 in HCC tumors correlates with global expression changes in N-linked 
glycoprotein-encoding genes. (A) Immunoblot of Golgi-resident proteins GM130, Vti1, syntaxin 6, and GS27 in HCC adjacent liver 
and tumor lysates. (B) Quantification of the immunoblots in panel A. Bars represent mean ± SD. *P < 0.05 compared to GS27; one-way 
ANOVA; Tukey’s multiple comparisons test. (C) Double immunofluorescence staining of GM130 (green) and DNA (blue) in adjacent 
liver and tumor tissue (representative images are from HCC case #752). Scale bars, 50 μm. Right panels show the respective magnified 
areas (represented by the yellow boxes). (D) RNAseq analysis on four pairs of HCC adjacent liver–tumor pairs revealing the percentage 
(36%-48%) of significantly differentially expressed genes that encode N-linked glycoproteins (complete data set is in Supporting File 
S2). (E) RNA expression levels of select N-linked glycoprotein genes (eNPP2, eNTPD8, and ADORA3) in paired HCC adjacent liver 
(black bars) and tumor tissues (gray bars). Each bar represents a single readout from the RNAseq data set (Supporting File S2). (F) 
Summary of findings and working hypothesis model of HCC tumor-specific changes in N-glycosylation. HCC tumors exhibit altered 
Golgi structure, as exemplified by significant overexpression of the structural protein GM130. Changes in Golgi structure lead to 
altered localization and decreased function of N-linked glycoproteins, including ecto-nucleotidase CD73, and are associated with 
decreased expression of eNPP2 and eNTPD8, leading to overall decreased levels in the production of extracellular adenosine. Decreased 
adenosine production by the highly mannosylated tumor CD73 blunts adenosine-dependent HCC cell death by the A3 adenosine 
receptor, promoting HCC progression. Abbreviations: A3AR, A3 adenosine receptor; ADO, adenosine; ADORA3, adenosine A3 
receptor gene; ADP, adenosine diphosphate; ATP, adenosine triphosphate; eNPP2, ectonucleotide pyrophosphatase/phosphodiesterase 
2 gene; FPKM, fragments per kilobase of exon model per million reads mapped; L, adjacent liver tissue; T, tumor tissue.
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RNA sequencing (RNAseq) analysis was per-
formed on two pairs of HCC specimens (adjacent 
tissue and tumor tissue) that displayed differences 
in CD73 migration on gel, as shown in insets to 
Fig. 6E. We additionally analyzed gene expression 
data on two HCC liver–tumor pairs from a pub-
lished RNAseq data set (GSE 33294). These results 
revealed that N-linked glycoprotein-encoding genes 
were among the most represented category of dif-
ferentially expressed genes (Fig. 6D;Supporting File 
S2). Because ecto-nucleotidases that act upstream of 
CD73 in the liver (e.g., ectonucleotide pyrophospha-
tase/phosphodiesterase 2 [eNPP2] and ectonucleoside 
triphosphate diphosphohydrolase 8 [eNTPD8]),(27) as 
well as the A3AR are also N-glycosylated, we com-
pared their gene expression levels in nontumor versus 
tumor tissue from the RNAseq sets. This comparison 
revealed a general decrease in expression (11%-95%) 
in the tumors compared to adjacent liver tissue (Fig. 
6E). Taking into account the RNAseq results and 
the molecular and biochemical studies, we propose a 
model for a tumor-selective mechanism to limit extra-
cellular adenosine signaling in HCC tumors by (i) 
disruption of CD73 glycosylation leading to decreased 
activity and (ii) transcriptional down-regulation of 
ecto-nucleotidases supplying the AMP substrate of 
CD73, such as eNTPD8 (Fig. 6F).
Discussion
CD73 as a potential taRget 
in HCC
HCC accounts for the vast majority of primary 
liver cancer cases, and there are ~850,000 new cases 
diagnosed worldwide each year.(28) While death 
rates continue to decline for most cancer types, 
recent trends in the United States reveal that liver 
cancer mortality has continued to increase at a rate 
of 2.5%-3% per year and 5-year survival remains 
below 20%.(29) At the onset of symptoms, HCC 
is typically advanced and not amenable to current 
treatment approaches, which are very limited. Direct 
modulation of adenosine receptor activity represents 
a promising therapeutic strategy for patients with 
HCC.(17) In addition to direct-acting agonists, such 
as the clinical candidate A3AR agonist CF102, 
an alternative approach is to augment the genera-
tion of the endogenous ligand adenosine. Here, we 
demonstrate that the adenosine-generating function 
of CD73 is compromised in human HCC tumors 
due to aberrant N-linked glycosylation. Aside from 
revealing a novel mechanism in HCC tumor biol-
ogy, our results may potentially help to identify 
patients who are more likely to benefit from A3AR 
agonists based on their tumor CD73 glycosylation 
status, localization, and activity. While our primary 
focus here was on tumor hepatocytes and HCC 
cells, the regulation and function of CD73 on other 
cell types, such as endothelial cells and lymphocytes, 
will need to be taken into account in future stud-
ies to determine if CD73 augmentation or blockade 
could be of potential benefit to patients with HCC.
DiFFeRenCes in CD73 
Regulation anD FunCtion 
aCRoss CanCeR types
Tumor-selective transcriptional up-regulation of 
NT5E can be protumorigenic as high expression 
of epithelial CD73 is associated with low levels of 
tumor-infiltrating leukocytes and reduced disease-free 
and overall survival in triple-negative breast cancer.(30) 
However, in contrast to breast cancer, CD73 is sig-
nificantly down-regulated in advanced endometrial 
tumors compared to normal endometrium and less 
aggressive tumors,(6,9) similar to invasive bladder can-
cer;(31,32) in both cases high expression predicts more 
favorable patient outcome. In the case of endometrial 
cancer, down-regulation of CD73 is detrimental as it 
leads to compromised integrity of the epithelial barrier. 
Specifically, CD73-generated adenosine is necessary for 
A1AR receptor-dependent cortical actin polymerization 
and cell–cell adhesion.(9) Our results herein reveal that 
posttranslational modulation of the CD73 nucleoti-
dase function by N-linked glycosylation is yet another 
important but underappreciated mechanism for modu-
lating CD73 function. Given our findings, assessment 
of CD73 expression by tissue staining alone does not 
necessarily reflect presence of the active enzyme as more 
detailed biochemical studies are needed to probe that 
function. Resolving which mode of CD73 regulation 
is most relevant for the specific tumor type will aid in 
understanding which patients are likely to benefit from 
CD73 blocking antibodies.
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tHe neeD FoR RoBust 
pReCliniCal IN VIVO stuDies 
on tHe Role oF CD73 in HCC
Studies examining how CD73 loss impacts 
HCC development in rodent models have not been 
performed, with the exception of a limited anal-
ysis reporting that subcutaneous inoculation of 
MHCC97-derived tumors showed decreased growth 
in CD73−/− compared to WT mice.(33) Use of global 
and tissue-specific CD73 knockout models in com-
bination with standard HCC induction models, such 
as chemical carcinogenesis, fatty liver disease, and 
alcohol-induced liver disease,(34) will help address this 
question in a rigorous manner in future studies. One 
major caveat is that CD73 regulation in humans is 
different from rodents, as we have shown to be the 
case with the posttranscriptional processing of the 
NT5E gene, which is uniquely spliced in humans 
compared to all other species.(22) Therefore, the use of 
humanized mice and patient-derived xenograft mouse 





Our prior and current results demonstrate that the 
major mechanism of CD73 regulation in HCC is not 
transcriptional but posttranscriptional(22) and post-
translational (current study). Previously, we demon-
strated that alternative splicing generates a novel 
human-specific CD73 isoform in cirrhosis and HCC 
(CD73S) that is present in both adjacent nontumor 
tissue and tumor tissue and acts in a dominant-nega-
tive fashion.(22) Our current results provide additional 
evidence that the activity of the major canonical CD73 
protein is selectively altered by N-linked glycosylation 
to produce a highly mannosylated and enzymatically 
impaired glycoform in HCC tumors. Understanding 
the pathways that lead to these changes may reveal 
additional molecular targets to elevate CD73 activ-
ity selectively in HCC tumors. For example, resto-
ration of Golgi morphology and glycosylation has 
been shown to enhance the susceptibility of prostate 
cancer cells to apoptosis,(35) and similar approaches 
may be explored in HCC. Our results may also 
help explain several previously reported functions of 
CD73 in multiple cell types that are independent of 
its activity as an AMPase, such as T-cell activation 
by protein–protein interactions to deliver a costimu-
latory signal,(36) promoting adhesion of lymphocytes 
to the endothelium,(37) conferring resistance to apop-
tosis of leukemia cells,(38) and inducing phosphoryla-
tion of intracellular proteins in response to antibody 
ligation.(39,40) Therefore, it is plausible that N-linked 
glycosylation is a mechanism to tune adenosine-inde-
pendent CD73 functions in different cell types under 
physiological and disease states.
CD73 as a maRKeR oF golgi 
oRganelle DysFunCtion in 
HCC tumoRs
The significant and selective up-regulation of 
GM130 in HCC tumors implicates the Golgi organ-
elle in HCC tumor biology. The Golgi apparatus is 
the central compartment of the secretory pathway 
where proteins and lipids are extensively modified as 
they traverse the organelle en route to their intended 
destination to cellular membranes or to being secreted 
outside the cell. Proper architecture of the Golgi, 
which is composed of stacks of cisternae, ensures that 
the various enzymes involved in the modification of 
proteins and lipids are localized to their proper com-
partment. The Golgi structural protein GM130 is 
critical for the lateral linking of Golgi elements, which 
in turn ensures the proper localization of glycosyla-
tion enzymes.(41) It was shown that down-regulation 
of GM130 had antitumor effects in a mouse model 
of lung cancer.(42) Presently, it is not clear what causes 
the Golgi alterations in cancer, but it is known that 
many genes, in particular kinases, exert control of this 
important organelle.(43) Therefore, the mechanism 
behind up-regulated GM130 expression in HCC 
tumors remains to be investigated and may involve 
kinome-level changes.
N-linKeD glyCosylation 
as a meCHanism FoR HCC 
pRogRession
Previous studies aimed at identifying serum bio-
markers reported major HCC-associated alterations 
in the types and abundance of glycans on specific 
serum proteins, such as α-fetoprotein and Golgi 
protein 73.(44-47) Aside from being a biomarker of 
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HCC, altered N-glycosylation can also serve a func-
tional role to promote HCC tumor metastasis. For 
example, altered N-glycan branching of CD147 
enhances its binding to β1-integrin to promote 
HCC tumor metastasis.(48) While the functional 
significance of elevated high-mannose glycans that 
we identified on HCC tumor CD73 is not clear, 
global high mannose glycosylation negatively affects 
multiple essential functions of the intestinal epi-
thelium, such as permeability, host–microbe inter-
actions, and the activities of membrane-associated 
proteins.(49) Therefore, it is plausible that the highly 
mannosylated CD73 tumor glycoform blocks the 
tissue barrier function of CD73.(6) This will be a key 
question for future studies.
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